BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1204 related articles for article (PubMed ID: 29307505)

  • 1. Practical considerations in medical cannabis administration and dosing.
    MacCallum CA; Russo EB
    Eur J Intern Med; 2018 Mar; 49():12-19. PubMed ID: 29307505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of Medical Cannabis.
    Amin MR; Ali DW
    Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
    Szaflarski JP; Bebin EM
    Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol - therapeutic and legal aspects.
    Vlad RA; Hancu G; Ciurba A; Antonoaea P; Rédai EM; Todoran N; Silasi O; Muntean DL
    Pharmazie; 2020 Oct; 75(10):463-469. PubMed ID: 33305718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
    Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
    Trials; 2024 May; 25(1):293. PubMed ID: 38693590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors.
    Brunetti P; Pichini S; Pacifici R; Busardò FP; Del Rio A
    Medicina (Kaunas); 2020 May; 56(5):. PubMed ID: 32429074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
    Freeman AM; Petrilli K; Lees R; Hindocha C; Mokrysz C; Curran HV; Saunders R; Freeman TP
    Neurosci Biobehav Rev; 2019 Dec; 107():696-712. PubMed ID: 31580839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
    Wade DT; Robson P; House H; Makela P; Aram J
    Clin Rehabil; 2003 Feb; 17(1):21-9. PubMed ID: 12617376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population.
    Highet BH; Lesser ER; Johnson PW; Kaur JS
    Am J Hosp Palliat Care; 2020 Aug; 37(8):589-593. PubMed ID: 31986898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.
    Allendorfer JB; Szaflarski JP
    Epilepsy Behav; 2017 May; 70(Pt B):349-354. PubMed ID: 28109780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cannabidiol (CBD) for the treatment of chronic pain.
    Urits I; Gress K; Charipova K; Habib K; Lee D; Lee C; Jung JW; Kassem H; Cornett E; Paladini A; Varrassi G; Kaye AD; Viswanath O
    Best Pract Res Clin Anaesthesiol; 2020 Sep; 34(3):463-477. PubMed ID: 33004159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.
    Todd SM; Arnold JC
    Br J Pharmacol; 2016 Jan; 173(1):53-65. PubMed ID: 26377899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of oral cannabis extracts in children with epilepsy.
    Knupp KG; Rice JD; Helmkamp LJ; Galinkin J; Sempio C; Jost K; Chapman KE
    Seizure; 2019 Nov; 72():23-27. PubMed ID: 31550641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoting cannabis products to pharmaceutical drugs.
    Koltai H; Poulin P; Namdar D
    Eur J Pharm Sci; 2019 Apr; 132():118-120. PubMed ID: 30851400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids in treatment-resistant epilepsy: A review.
    O'Connell BK; Gloss D; Devinsky O
    Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.